Life Sciences Archive » September, 2012

Life Sciences - September, 2012

237 articles

• Fed. Circ. Backs Ban On Generic Treximet
• FDA Approves Wider Humira Use Despite Efficacy Concerns
• Jury Hears From Teen Boy's Doc At Risperdal Trial
• Novartis Escapes Long-Running Farmers' Pesticide Suit
• Brand-Name, Generic Reglan Makers Beat Injury Suit
• FDA Loss May Draw Drug-Device Makers To Policy Fight
• Dentsply Can't Ax Suit Alleging Dental Tool Defects
• Sham Litigation Claims Nixed In Androgel Pay-For-Delay MDL
• Abbott Diabetes Monitor Patent Revived By Fed. Circ.
• Healthpoint Settles $90M Medicaid Fraud Suit Over Xenaderm
• Vivus Escapes Shareholder Suit Over Obesity Drug Safety
• JPML Ships 5 Fen-Phen Suits Against Wyeth, Pfizer To Pa. MDL
• Medtronic Goes Wide In China With $816M Device Maker Buy
• Stryker Says Wright Medical Copied Implant Name For Website
• Food Labeling Suits: An Explosive Trend In Tort System
• GAO Calls For Greater FDA Scrutiny On Device Hacking Risk
• Boehringer Can Keep Many Docs On Barr Deal Away From FTC
• Lilly Nets Another 2nd Circ. Win In Zyprexa MDL
• Medicare Wrongly Paid $25M For Painkiller Refills, HHS Says
• Novartis Wants Pesticide Suit Nixed For Discovery Failing
• Obama, Romney Duel Over Health Care Ahead Of 1st Debate
• Reckitt Asks FDA To Require Opioid Drug Childproofing
• Top 5 Corruption Risks For Pharmaceutical Cos.
• Bayer, Class Reach Deal In One-A-Day Prostate False Ad Suit
• Judge To Keep J&J CEO Off Stand In Risperdal Case
• Pain Therapeutics Gets Investors' Painkiller Suit Nixed
• Breast Implant Scandal Spurs EU To Strengthen Device Regs
• Smith & Nephew Issues Warning On Metal Hip Device
• J&J Can't Use Mensing To Keep Metal Hip Case Federal
• New Plan To Double Drug Approvals Offers Few Fresh Ideas
• HHS Passes Clinical Trial Reporting Authority To FDA
• Merck Investors Win Class Cert. In 2 Suits Over Vytorin
• Philly Court Boots Accutane Cases From Mass Tort System
• Astellas Skirts $867M Antitrust Suit Over Heart Test Drug
• Biopharma Co. Sues Over Cancer Drug Clinical Trial Mix-Up
• FDA Wrongly Denied Orphan Drug Exclusivity, Depomed Claims
• Shareholder Sues Life Science Co. Over $118M Merger
• AstraZeneca To Pay $11M To Settle Toprol-XL Antitrust Claims
• Jury Finds For J&J Unit In Row Over Abbott Antibody Patents
• McDermott Gets Go-Ahead To Work Tekmira Patent Case
• Breg Can't Escape Pain Pump Injury Suit
• Bayer, Others Ask High Court To Review Pay-For-Delay Case
• Janssen Promoted Risperdal Off Label, Jury Hears
• FDA Issues Guidance On Proving Generic-Drug Stability
• Stryker Recalls Neptune Devices After Death Reported
• Roche Bid Raises Prospect Of Mass Tort Exodus From Philly
• DOJ Unlikely To Spend Scarce Time, Money On Olympus Case
• Justices Expected To Write Final Chapter On Gene Patents
• 9th Circ. Affirms Merck's Win In Vaccine Wrongful Death Suit
• Patient Suing Stryker Can't Get Calif. Hospital Records
• Arnold & Porter Accused Of 'Egregious' Conflict In Patent Case
• Case Study: In Re Rigel Pharma Securities Litigation
• Ethypharm Urges 3rd Circ. To Revive Abbott Antitrust Row
• Fundamental Research Can Still Implicate Export Controls
• King & Spalding Lands IP Deals Pro From Davis Polk
• Metal Implant Patients Should Get Blood Tests, Australia Says
• Warner Chilcott Hit With Suit Over Doryx Market Misdeeds
• Risperdal Caused Teen Boy's Breast Growth, Jury Hears
• LabCorp Says VA Slammed Door On Its $32M Contract Bid
• Covidien Unit To Buy Specialty Drug Co. For $100M
• USTR Takes Israel Off IP Priority Watch List
• New FDA Team Seeks To Spur Antibiotics Innovation
• Judge Pares Suit Over Pfizer's Yanked Feed Additive
• Health Care Pro Joins Edwards Wildman From DOJ
• Merck To Pay Up To $10M To Settle Coppertone False Ad Suit
• Bankrupt K-V Fights Hologic Bid To Reacquire Makena Rights
• Fed. Circ. Knocks Inventors' DNA Patent As Too Obvious
• Congress OKs Last-Minute Fix To Save $250M In FDA Fees
• Ill. Can't Make Pharmacists Dispense Plan B, Court Says
• Freshfields Guides Advent In Proposed $1B Mediq Buy
• Avoiding OSHA Citations In Food And Beverage Industry
• EU Committee Backs Pfizer-BMS Anti-Clotting Drug
• IRS Can't Dodge Bayer's $65M Tax Credit Suit
• SEC Sues Syringe Maker For Allegedly Inflating Stock
• Drug Biz Worried Over User Fees' Fate Under Sequestration
• Church & Dwight Should Ax 'First, Only' Ovulation Claim: NAD
• Cytori Protests FDA's Cold Shoulder Toward Its Devices
• Mixing Agency Rules May Mean More Taxable Medical Devices
• Stryker Pays $1.5M To End Investors' Kickback, FCA Suits
• Three Bayer Probiotics False Ad Class Actions Revived
• Orthofix, Pfizer FCPA Cases A Sign Of What's To Come
• Gerber Urges MDL Panel To Consolidate Baby Formula Suits
• SLU's $7M Medtronic Royalties Suit Removed To Colo.
• NuVasive Says J&J Units Poached Medical Device Sales Rep
• J&J CEO Won't Take Stand In Risperdal Breast-Growth Trial
• Obama Admin's Welfare Waiver Rule Snubbed By House
• Biomet Raises Specter Of New Suits To Fight Hip-Implant MDL
• FTC Sets Sights On High Court Pay-For-Delay Fight
• Roche Picks NY Over NJ For New Research Center Location
• Santaris Can't Skirt Isis Suit Over Drug Development Deals
• Spotlight On BPA: Science And Litigation
• Watson Sued By Fertility Drug Rival Over Ad Campaign
• Osteoarthritis Pills Tainted With Lead, Class Action Says
• Politics Delay Senate Vote On 6-Month Stopgap Budget
• Baxter Execs Beat Investor Suit Over $588M Pump Recall
• House Clears Bipartisan Bill To Ramp Up Pediatric Research
• Novartis Prevails In Cancer Patient's Zometa Injury Suit
• FDA Tells High Court Warning Letters Aren't Final Actions
• Allergan Secretly Records Customer Calls, Suit Says
• Chantix Plaintiffs Can Gun For Punitive Damages In Bellwether
• Public Health Pro Rejoins Ropes & Gray From Harvard
• McKesson Pegged With Price Inflation Claims On 400-Plus Drugs
• Judge Keeps Sales Ban In Cephalon Generic Amrix Patent Row
• Doctor Convicted On False Fen-Phen Injury Claims
• Gibson Dunn Nabs Life Sciences IP Partner For Dallas Office
• Latham Guides Boston Scientific's Heart Catheter Maker Buy
• Pfizer Loses Bid To Invalidate Bayer's Bovine Drug Patent
• Mirapex May Increase Heart Failure Risk, FDA Says
• Bard Beats Contract Claim In Catheter Trade Secrets Fight
• Prescriptions For Life Science Investing
• New Concepts Under FTC Rule For Pharma Patent Deals
• Lessons From In Re Rigel Pharmaceuticals
• Pfizer's Neurontin Marketing Hurt Payors, 1st Circ. Hears
• Pharmacies Ill-Prepared For Potential DEA Crackdown
• Ariosa Asks USPTO To Nix Sequenom Prenatal Test Patent
• Attys Want J&J CEO To Testify In Risperdal Breast-Growth Case
• FDA Issues Warning For Over-The-Counter Diarrhea Drug
• Fed. Circ. Clarifies Burden Of Proof In Medtronic IP Case
• Wyeth Investors Win Class Cert. In Suit Over Pristiq Risks
• FDIC, Insurers Reach Deal In $25M Westernbank Claim Fight
• Plavix False Marketing Suit Kicked To State Court
• Merck Bashes Lawsuits Over Prescription Copay Coupons
• RICO Suit Over Sanofi Antibiotic Should Be Tossed, Judge Says
• Merck Strikes Damages Deal In Fosamax Bellwether Case
• Apotex Defeats Allergan's New Suit Over Pinkeye Patent
• Alaven Seeks $10M From Insurers For Reglan Defense
• Past Metal-Hip Fights May Haunt Biomet's Bid To Avoid MDL
• Avandia Heart Attack Plaintiffs Want Suits Out Of MDL
• Harvard Sues USPTO For Invalidating Mice-Testing Patent
• Democrat Moves To Allow Medicare Drug Price Negotiations
• O'Melveny Reps Chinese Co. In $118M Complete Genomics Deal
• GE, Cardinal Escape Antitrust Class Action Over Imaging Drug
• Pfizer Tells High Court Bankruptcy Law Protects Parent Cos.
• Judge Tosses FCA Suit Over Purdue's OxyContin
• Male Supplement Fails To Live Up To Hype, Suit Says
• Actelion Sues To Keep Tracleer Away From Apotex, Roxane
• Calif. Court Upholds Ex-Sequenom Exec's Defamation Claim
• FDA Budget To Plunge By $319M If Sequester Takes Effect
• K-V Gets Judge's OK To Use Cash Collateral To Boost Biz
• Impax Settles IP Row With J&J Over Generic Concerta
• RSUI Off Hook For $65M Forest Lab Drug Info Settlement
• Widow Urges High Court To Hear Novartis Bone Drug Dispute
• FDA Gives Medical Device Makers More Time To Mull ID Rule
• Avanir Sues Rivals Over Plans For Generic Neurological Drug
• Taking Stock: The AIA At 1 Year
• A Primer On Alternative Fee Arrangements
• Bayer Snaps Up Teva Animal Health Unit In $145M Deal
• House Passes Stopgap Bill To Fund Government For 6 Months
• Greenberg Traurig Still On Hook For Burned Doc, Atty Says
• McKesson Investor Targets Execs Over Drug Price-Rigging
• Fla. Man Gets 10 Years For $55M Drug Diversion Scheme
• Neogenix — A Cautionary Tale
• House Panel Moves To Block HHS Welfare Waiver Rule
• Bengay, Other Pain Relievers Can Cause Burns, FDA Says
• Morgan Lewis Helps Perrigo Fetch Pet Care Co. For $285M
• Regeneca Latest To Receive DMAA Warning From FDA
• $52M Jury Verdict Overturned In Gene Test Patent Row
• Down On The Farm Bill: A Drought-Like Outlook
• Eye Med Distributor Lobs $100M Suit Over Supply Contract
• OTC Drug Ads Rarely Mention Risks, Study Finds
• Novel Latest Drugmaker Sued By Purdue Over Insomnia Drug
• TPG's $2B Par Pharma Buyout Bid Harms Investors, Suit Says
• Blackstone Can't Claim $4M For Sun Pharma Deal, Taro Says
• Medicis Investor Sues To Halt $2.6B Valeant Buyout
• Merck & Cie Tells ITC Rivals Infringed Supplement Patents
• 3SBio Priced At $331M In Go-Private Buyout Offer
• Braintree Takes Cypress To Court Over Generic Suprep
• FCC Spectrum Commitment Opens Door To Mobile Medical Care
• Otsuka Targets Apotex In Latest Suit Over Generic Abilify
• Addressing The Scope Of CAFA In Supreme Court
• DEA Strips 2 CVS Pharmacies Of Drug Licenses
• Stryker Hit With 7 More Suits Over Metal Hip Implants
• House Mulls Quick-Fix Spending Bill To Buy 6 More Months
• Life Sciences Rise In Value Despite Venture Capital Dropoff
• J&J Wins Patent Dispute Over Birth Control Drug
• EU Lawmakers Vote To Strengthen Drug Safety Regime
• FDA Test-Drives New Risk-Benefit Framework
• Wyeth Asks Pa. High Court To Drop $8.6M Prempro Punitives
• FCPA Liability In M&A: Lessons From Pfizer Settlements
• Medicare Medical Equipment Bidding Flawed, Panel Hears
• Mayer Brown Scores Kilpatrick Patent Litigation Pro
• Ex-Pharmacy Directors Hit UHS, Drugmakers With FCA Suit
• Industry Points Out Transparency Issues With FDA Device Plan
• 9th Circ. Vacates $60M NuVasive Trademark Verdict
• J&J Settles Pa. Risperdal Lawsuit On Opening Day Of Trial
• Doctor Accuses J&J, Others Of Treading On Surgical Patents
• Xanodyne Gets Most State Claims Booted From Darvocet MDL
• MannKind To Pay $23M In Investor Suit Over Diabetes Drug
• GSK Not Liable For Homicide Linked To Paxil Generic: Judge
• Kimberly-Clark, Cardinal Renew Surgery Scrubs False Ad Fight
• Stryker Will Pay $4.25M To End Sales Rep Expense Claims
• Pfizer Hit With $5M Jury Verdict In Prempro Battle
• Medical Device Maker Seeks To Escape Soured Sales Deal
• Salix, Dr. Falk Sue Lupin Over Generic Version Of Apriso
• 2nd Circ. Lets Lilly Off Hook In Zyprexa Diabetes Suit
• Health Issues Top Agenda As Congress Returns
• FDA Eyes More Savvy Post-Approval Device Monitoring
• CORRECTED: Jefferson Gets Dibs On Patents From Cancer Doc's Research
• Pain Patch Maker Demands Coverage Of False Ad Suit
• Spotlight On Calif.'s Food Labeling Lunge
• Novartis Ruling Helps NJ Drug Cos. Fend Off Punitive Damages
• K-V Can't Challenge FDA Enforcement Decisions, Judge Rules
• PSLRA Claims Need Proof Of False Statements: 9th Circ.
• FDA Beats EU On Cancer Drugs, But Not Others, Study Shows
• Genentech, Xoma Beat Raptiva Warning Suit In 6th Circ.
• GAO Welfare Ruling Adds Congress To Agency Rulemaking Mix
• HHS Must Focus On Health IT For Crucial Reforms, IOM Says
• Shire Settles Patent Battle With Par Unit Over ADHD Drug
• Judge Nixes $7.8M Orthofix Medicare Fraud Plea
• Morgan Lewis Lures Food And Drug Team From K&L Gates
• Hologic Asks To Pursue Makena Claims Against K-V Pharma
• Fresenius Can't Stay Fed. Circ. Appeal Of $24M IP Judgment
• Smith & Nephew Wins $4M In Surgical Device Patent Suit
• Age Of The Whistleblower: Incentives And Protections
• FDA Fast-Track Program May Harm Patient Safety, Study Says
• Genzyme, Impax Bury Hatchet Over Kidney Disease Drugs
• Sunshine Act Authors Urge CMS To Finalize Rule
• Choate Takes On Life Sciences Co-Chair From Infinity Pharma
• Skadden Adds Ex-WilmerHale Global Corporate Head In Boston
• Celera Can't Duck Shareholder Suit Over Financial Reports
• FDA Sued Over Delay On Pfizer Alzheimer's Drug Decision
• FDA Fights Back Against ViroPharma's Generic Vancocin Suit
• Bayer Beats FCA Suit Over Off-Label Yaz Marketing
• Cozen O'Connor Bolsters IP, Insurance Groups With 2 Hires
• Fed. Circ. Revives Santarus' Suit Over Par's Generic Zegerid
• Ropes & Gray Boosts DC Life Sciences Group With PE Pro
• Merck Resolves $220M Vioxx Loss Claims In 5th Circ.
• Democrats Say ACA Not End of Health Reform
• Seyfarth Shaw Lands Apotex's Ex-IP Head For Chicago Office
• Merge, Commed Hit With FDA Warnings Over Facility Violations
• Ex-Bayer Exec Says Criticism Of Aleve Claims Led To Firing
• GSK Whistleblowers Slam 'Excessive' $30M Fee Request
• Parents Say Wyeth's Effexor Caused Birth Defects
• GSK ERISA Class Action Overblown, 2nd Circ. Says
• Celgene, Agios Settle $1B UPenn Cancer Research Suits
• Sullivan, Skadden Rep Valeant In $2.6B Skin Care Co. Buy
• The Practical Lessons Of Myriad